埃文克Industrieshas launched a new website aimed specifically at manufacturers of oncology drugs. The new site,www.evonik.com/oncology-drugs, provides pharmaceutical companies with an overview of Evonik's competencies in this space. They include a proven track record in production of high-potency actives, development of drug delivery systems, generation of clinical samples, and commercial-scale manufacture of parenteral oncology drug products.
“The development and manufacturing of effective cancer drugs present significant challenges. Evonik with its broad competencies can help pharmaceutical companies overcome these hurdles and accelerate the development process." said Dr. Jean-Luc Herbeaux, the head of the Health Care Business Line of Evonik. The new website describes the company’s Hanau, Germany, and Tippecanoe, U.S., sites’ capacities to produce highly potent active pharmaceutical ingredients (HPAPIs) in any volume from laboratory to commercial scale.
It also describes the pharmaceutical polymer platforms of Evonik, EUDRAGIT® and RESOMER®, which afford options to manufacture intelligent drug delivery systems for oral and parenteral administration. Thanks to their targeted and controlled release, these polymer contribute to reducing the dosage and cancer therapy length for the patient's benefit. Evonik is also able to support pharmaceutical companies with formulation development. To give an example, Evonik has expertise in spray drying and melt extrusion, which can overcome the bioavailability problems that frequently occur with HPAPIs.
The company's certified facilities in Darmstadt, Germany and Birmingham, U.S. allow for the production of clinical samples for phase II (oral) and III (parenteral) trials. The Birmingham site is also equipped to produce a broad spectrum of complex parenteral drug systems for cancer therapies, such as micro-size and nanoparticles, liposomes, or lyophilisates. "Thanks to our global presence, competencies in many areas of drug development, unique technologies and ultra-high quality standards, we are well positioned to support our pharmaceutical customers in their development projects," notes Herbeaux.
关于Evonik
埃文克，来自德国的创意工业集团是特种化学品的世界领导者之一。盈利的增长和公司价值的持续增长构成了Evonik公司战略的核心。它的活动着重于关键的大型健康，营养，资源效率和全球化。Evonik从其创新的实力和集成技术平台中特别受益。
埃文克（Evonik）活跃于全球100多个国家。在2012财年，超过33,000名员工的销售额约为134亿欧元，营业利润（调整后的EBITDA）约为24亿欧元（两种情况下不包括房地产）。